Context Therapeutics posts results for terminated elacestrant-onapristone breast cancer trial
The ELONA Phase 1b-2 study combining elacestrant and onapristone was stopped early after Context Therapeutics decided to halt onapristone's development, with only 4 patients enrolled.
The week's sole update concerns a discontinued combination trial in ER-positive, PgR-positive, HER2-negative breast cancer.
- "ELONA" (NCT05618613), a Phase 1b-2 study of elacestrant combined with onapristone in advanced or metastatic ER+/PgR+/HER2- breast cancer, has results first posted with a status of terminated. The study was stopped due to a sponsor decision to discontinue onapristone development.1 The trial started December 2, 2022, with primary and study completion both recorded as June 23, 2023, and results were first posted July 21, 2026.1 Actual enrollment reached only 4 participants.1 The Phase 2 objective response rate endpoint was never assessed because Phase 2 was not initiated and no patients were enrolled in that portion.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.